Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Panion & Bf Biotech (TPE:1760) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Panion & Bf Biotech Forward PE Ratio Related Terms
Panion & Bf Biotech Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Panion & Bf Biotech's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Panion & Bf Biotech Forward PE Ratio Chart
Panion & Bf Biotech Annual Data
Trend
2024-12
2025-12
Forward PE Ratio
47.33
34.48
Panion & Bf Biotech Quarterly Data
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
47.33
45.23
41.59
37.92
34.48
34.64
TPE:1760 vs ZTS: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Panion & Bf Biotech's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Panion & Bf Biotech Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Panion & Bf Biotech's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Panion & Bf Biotech's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Panion & Bf Biotech (TPE:1760) has a Forward PE Ratio of 32.30 as of Aug. 12, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Panion & Bf Biotech and its competitors. According to the industry distribution chart, Panion & Bf Biotech ranks #308 out of 408 companies in the Drug Manufacturers industry, placing it in the top 75.5%.
Is Panion & Bf Biotech's Forward PE Ratio too high?
Panion & Bf Biotech's current Forward PE Ratio is 32.30. The Drug Manufacturers industry median Forward PE Ratio is 17.55. Panion & Bf Biotech's value of 32.30 is 84% above this industry median. Based on the distribution chart, Panion & Bf Biotech ranks #308 out of 408 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Panion & Bf Biotech has a GF Score™ of 73/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Panion & Bf Biotech's Forward PE Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Panion & Bf Biotech ranks #308 out of 408 companies for Forward PE Ratio. This places Panion & Bf Biotech in the lower half of its industry. The industry median Forward PE Ratio is 17.55. Panion & Bf Biotech's value of 32.30 is 84% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.55, based on 408 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Panion & Bf Biotech's current Forward PE Ratio of 32.30 is 84% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Panion & Bf Biotech and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Panion & Bf Biotech's current Forward PE Ratio is 32.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Panion & Bf Biotech stock overvalued right now?
Based on GuruFocus' analysis, Panion & Bf Biotech (TPE:1760) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$90.03, compared to a current price of NT$58.80 — trading 34.7% below its estimated fair value. The current Forward PE Ratio is 32.30 and 84% above the Drug Manufacturers industry median of 17.55. Panion & Bf Biotech's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Panion & Bf Biotech (TPE:1760), the current Forward PE Ratio is 32.30 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Panion & Bf Biotech (TPE:1760) Overvalued in 2026?
Based on GuruFocus' analysis, Panion & Bf Biotech stock appears to be undervalued.
The current stock price of NT$58.80 is trading 34.7% below its estimated GF Value™ of NT$90.03.
GuruFocus considers Panion & Bf Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1760:
Forward PE Ratio: 32.30
GF Value™: NT$90.03 vs. price of NT$58.80 (34.7% below fair value)
Industry Position: 84% above the Drug Manufacturers median (#308 of 408)
No single metric tells the full story. See the TPE:1760 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company, along with its subsidiaries, is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups: disease treatment, disease prevention, disease diagnosis, and delayed aging. It has geographic segments in Taiwan; China, Hong Kong, and Macau; the USA; and Korea. It generates a majority of its revenue from the Taiwan segment. Product-wise the firm generates the majority of its revenue from Pharmaceutical products.
73GF Score
Get the complete analysis for TPE:1760
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1760 has been successfully added to your 
